SHPHShuttle Pharmaceuticals Hol...

Nasdaq shuttlepharma.com


$ 1.67 $ -0.06 (-3.49 %)    

Wednesday, 18-Sep-2024 15:57:53 EDT
QQQ $ 472.49 $ -2.05 (-0.43 %)
DIA $ 416.26 $ -1.07 (-0.26 %)
SPY $ 562.20 $ -1.67 (-0.3 %)
TLT $ 99.62 $ -1.25 (-1.24 %)
GLD $ 235.53 $ -1.83 (-0.77 %)
$ 1.66
$ 1.79
$ 1.67 x 200
-- x --
$ 1.67 - $ 1.79
$ 1.28 - $ 5.76
124,877
na
3.7M
$ 4.05
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 09-04-2024 06-30-2024 10-Q
2 05-13-2024 03-31-2024 10-Q
3 03-21-2024 12-31-2023 10-K
4 11-13-2023 09-30-2023 10-Q
5 08-14-2023 06-30-2023 10-Q
6 05-25-2023 03-31-2023 10-Q
7 03-15-2023 12-31-2022 10-K
8 11-14-2022 09-30-2022 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 shuttle-pharmaceuticals-expands-phase-2-clinical-trial-of-ropidoxuridine-for-glioblastoma-treatment-to-two-additional-sites-bringing-total-to-four-ready-for-patient-enrollment

Participating Centers Include UVA Cancer Center, John Theurer Cancer Center, AHN Cancer Institute, And Miami Cancer Institute

 why-shuttle-pharmaceuticals-shph-is-extremely-volatile-today

Shuttle Pharmaceuticals shares fell 4.6% to $2.26 Thursday morning after earlier gains. The move lower comes despite announcing...

 shuttle-pharmaceuticals-granted-us-patent-12077515-for-selective-histone-deacetylase-inhibitors-to-treat-human-diseases

https://ppubs.uspto.gov/dirsearch-public/print/downloadBasicPdf/12077515?requestToke[…]kYTczNGM0Ny0xZTJmLTRiZjctYTBhOC05ZDU3MWE...

 shuttle-pharma-regains-compliance-with-nasdaq-minimum-bid-price-requirement

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharma" or the "Company"), a discovery and devel...

 shuttle-pharma-on-pace-to-enroll-patients-in-phase-2-clinical-trial-of-ropidoxuridine-for-treatment-of-glioblastoma

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharma"), a discovery and development stage specialty ph...

 shuttle-pharmas-selective-hdac-inhibitor-exhibits-ataxia-telangiectasia-mutated-protein-activation-and-modulation-of-er-expression-resulting-in-growth-inhibition-of-estrogen-receptor-positive-breast-cancer-cells-as-reported-in-public-library-of-science-one

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH), ("Shuttle Pharma"), a discovery and development stage specialty p...

 shuttle-pharmaceuticals-q1-eps-010-down-from-007-yoy

Shuttle Pharmaceuticals (NASDAQ:SHPH) reported quarterly losses of $(0.10) per share. This is a 42.86 percent decrease over los...

 why-macatawa-bank-shares-are-trading-higher-by-around-37-here-are-20-stocks-moving-premarket

Shares of Macatawa Bank Corporation (NASDAQ: MCBC) rose sharply in today’s pre-market trading after Wintrust Financial Corpora...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION